Forte Biosciences Taps Market for $150M to Fund Pivotal Drug Trials

DALLAS, TX – April 08, 2026 – Clinical-stage biopharmaceutical company Forte Biosciences is moving to bolster its finances, announcing a proposed public offering expected to raise approximately $150 million. The move comes on the heels of a remarkable surge in its stock price and is designed to fuel the advancement of its lead drug candidate through a series of critical clinical trials in the coming year.

The Dallas-based company, which focuses on developing therapies for autoimmune diseases, priced the offering at $26.27 per share. The proceeds are earmarked for working capital and, most importantly, to fund the ongoing clinical development of its primary asset, FB102.

Capitalizing on Market Momentum

Forte's decision to raise capital now appears strategically timed to leverage significant investor enthusiasm. The company's stock (NASDAQ: FBRX) has been on an impressive run, gaining a staggering 361% over the past year and 74% in the last six months alone. Just prior to the offering announcement, shares closed at $25.58 on April 2.

While issuing new stock can lead to dilution for existing shareholders, the strategy allows a company to capitalize on a high valuation to secure funding. For a pre-revenue company like Forte, a strong cash position is paramount. The offering, managed by Guggenheim Securities and Barclays as joint book-runners, is expected to close around April 10, 2026.

Despite the positive momentum, some market analysis suggests caution. The stock's high volatility, indicated by a beta of 3.2, and a valuation that some analysts consider stretched relative to fundamentals, underscore the high-risk, high-reward nature of investing in clinical-stage biotech. This offering provides a crucial cash cushion to navigate that volatility.

The High Stakes of Drug Development

The capital infusion is essential for Forte Biosciences, which operates in the cash-intensive world of pharmaceutical research and development. Like most of its clinical-stage peers, the company does not yet have a product on the market and generates no revenue. Its survival and success depend entirely on its ability to fund its research pipeline.

According to its latest financial filings, Forte held $77.0 million in cash and cash equivalents as of December 31, 2025. With an annual cash burn rate of approximately $45 million, this new financing significantly extends the company's operational runway. This is a familiar strategy for the company, which has consistently tapped the equity markets, raising around $75 million in 2025 and $53 million in 2024 to keep its research programs moving forward. The company's accumulated deficit of $223.4 million as of its last annual report highlights the long and expensive path to bringing a new drug to market.

The net proceeds from this $150 million offering will provide the necessary resources to advance its clinical programs without the immediate pressure of an impending cash crunch, allowing management to focus on achieving its scientific milestones.

FB102: A Pivotal Year for a Promising Candidate

At the heart of Forte's strategy and the rationale for the capital raise is FB102, a proprietary monoclonal antibody with the potential to treat a wide range of autoimmune and autoimmune-related conditions. The drug targets the CD122 receptor, which plays a key role in modulating the immune system's response.

The coming year is set to be pivotal for both the drug and the company, with three major clinical trial readouts anticipated in 2026. This confluence of data makes the current funding round critically important.

The most advanced program is in celiac disease. In June 2025, Forte reported positive data from a Phase 1b trial where FB102 demonstrated statistically significant improvements in key histological markers and a 42% reduction in gluten-induced symptoms compared to a placebo. Building on that success, the company has initiated a larger Phase 2 trial (FB102-301), with topline results expected in 2026.

Beyond celiac disease, Forte is exploring FB102's potential in other conditions. A Phase 1b study in vitiligo, a skin condition causing loss of pigment, is ongoing, with data expected in the first half of 2026. Another Phase 1b trial for severe alopecia areata, an autoimmune disease causing hair loss, has also begun enrolling patients, with results similarly slated for 2026. Success in any of these indications could open up multi-billion dollar market opportunities and validate the drug's mechanism of action for even broader applications, such as graft-versus-host disease (GVHD) and type 1 diabetes.

Navigating a Shifting Biotech Funding Landscape

Forte's offering is taking place within a complex but improving funding environment for the biopharmaceutical industry. After a volatile and challenging 2025, market sentiment began to rebound late in the year. While the number of biotech initial public offerings has remained modest in early 2026, the size of financing rounds has grown significantly.

This trend indicates that investors are becoming more selective, directing larger amounts of capital toward companies with compelling, de-risked assets and clear clinical pathways—a category that Forte, with its mid-stage candidate and positive Phase 1 data, arguably falls into.

Furthermore, a surge in merger and acquisition activity, driven by large pharmaceutical companies looking to replenish their pipelines as major drugs go off-patent, has renewed interest in the sector. Small and mid-sized biotechs with promising candidates in late-stage development are seen as prime acquisition targets. By securing substantial funding now, Forte not only finances its operations but also strengthens its negotiating position for any potential future partnerships or acquisitions, ensuring it can advance FB102 from a position of financial strength. This offering ensures the company has the resources to see its key 2026 data readouts through to completion, a crucial step in determining the future of both its lead drug and the company itself.